SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.3% – Should You Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price shot up 9.3% during trading on Friday . The company traded as high as $5.50 and last traded at $5.4970. 2,028,063 shares changed hands during trading, a decline of 76% from the average session volume of 8,385,827 shares. The stock had previously closed at $5.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.00.

SELLAS Life Sciences Group Price Performance

The stock has a 50-day simple moving average of $4.33 and a 200-day simple moving average of $2.76. The stock has a market cap of $774.87 million, a PE ratio of -19.41 and a beta of 2.18.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several institutional investors have recently bought and sold shares of SLS. Axxcess Wealth Management LLC acquired a new stake in shares of SELLAS Life Sciences Group in the third quarter worth $26,000. Larson Financial Group LLC acquired a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at $26,000. BNP Paribas Financial Markets lifted its holdings in shares of SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new stake in SELLAS Life Sciences Group during the 4th quarter worth $38,000. Finally, Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group in the 4th quarter valued at $38,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.